Research
Epitranscriptomics & Cancer Adaptation : A.David

Activities

Our research work focuses on the contribution of post-transcriptional mechanisms on cancer cell adaptation, in particular RNA epigenetic & translational control.

More..

Zotero public

Added by pcoopman
Last modified by standudu
Group name EquipePC
Item Type Journal Article
Title Decision of Adjuvant Systemic Treatment in HR+ HER2- Early Invasive Breast Cancer: Which Biomarkers Could Help?
Creator Alexandre et al.
Author Marie Alexandre
Author Aurélie Maran-Gonzalez
Author Marie Viala
Author Nelly Firmin
Author Véronique D'Hondt
Author Marian Gutowski
Author Céline Bourgier
Author William Jacot
Author Séverine Guiu
Abstract The decision to administer adjuvant chemotherapy in treatment of early invasive breast cancer (EBC) is often complex, particularly for hormone receptor-positive (HR+) diseases, and current guidelines often classify these patients in an intermediate-risk group. Several biomarkers are currently available in this indication, in order to obtain additional and more accurate prognostic information compared to classic clinicopathological characteristics and guide the indication of adjuvant chemotherapy, optimizing the efficacy/toxicity ratio. We conducted a systematic review to evaluate the clinical validity and clinical utility of five biomarkers (uPA/PAI-1, OncotypeDX®, MammaPrint®, PAM50, and EndoPredict®) in HR+/HER2- EBC, whatever the nodal status. A total of 89 studies met the inclusion criteria. Even though data currently available confirm the clinical validity of these biomarkers, there is a lack of data regarding clinical utility for most of them. Prospective studies in well-defined populations are needed to integrate these biomarkers in a decision strategy.
Publication Cancer Management and Research
Volume 11
Pages 10353-10373
Date 2019
Journal Abbr Cancer Manag Res
Language eng
DOI 10.2147/CMAR.S221676
ISSN 1179-1322
Short Title Decision of Adjuvant Systemic Treatment in HR+ HER2- Early Invasive Breast Cancer
Library Catalog PubMed
Extra 00000 PMID: 31849525 PMCID: PMC6912012
Tags breast cancer, clinic
Date Added 2020/07/17 - 17:59:13
Date Modified 2020/10/04 - 14:01:58
Notes and Attachments PubMed entry (Attachment)
Texte intégral (Attachment)


© Institut de Recherche en Cancérologie de Montpellier - 2011 - Tous droits réservés - Mentions légales - Connexion - Conception : ID Alizés